Lymphodepletion-Free Intra-CSF versus Intravenous Infusion of CD19/CD22 Bispecific CAR-T for Adults with Relapsed/Refractory CNS B-Cell Malignancies

The central nervous system, the brain and spinal cord, is a fortress protected by a highly selective barrier that keeps most substances in the blood from entering. While this protection is vital for health, it becomes a deadly obstacle when cancer spreads to this area. Standard chemotherapy drugs often cannot cross this barrier, leaving tumors in the brain or the fluid surrounding it largely untouched. For decades, doctors have struggled to treat these isolated cancers, which often return quickly and are difficult to control. A newer type of treatment, known as CAR-T therapy, has shown great promise for blood cancers by reprogramming a patient's own immune cells to hunt down and destroy cancer cells. However, when this therapy is delivered through a vein into the whole body, it faces two major problems: the immune cells struggle to cross the barrier to reach the brain, and the treatment often causes severe side effects throughout the body, requiring patients to undergo harsh chemotherapy beforehand to make room for the new cells.

A team of researchers at Nanchang University and collaborating institutions decided to try a different approach. Instead of sending the engineered immune cells through the bloodstream, they delivered them directly into the cerebrospinal fluid, the liquid that cushions the brain and spinal cord. This method, called intra-cerebrospinal fluid delivery, bypasses the protective barrier entirely, placing the treatment right where the cancer lives. In a recent study, the team tested this strategy in nine adults with aggressive B-cell cancers that had returned in the central nervous system. They used a specialized version of CAR-T cells designed to recognize two different targets on the cancer cells, making it harder for the disease to hide. Crucially, they administered these cells without the usual pre-treatment chemotherapy, aiming to see if this direct route could be both safer and more effective than the standard method.

The results of this small but detailed study were encouraging. Of the nine patients who received the treatment, seven showed a positive response, and six achieved a complete remission, meaning no signs of the cancer could be detected at the time of evaluation. The researchers found that the treatment worked quickly, with many patients seeing their symptoms improve within weeks. Perhaps most significantly, the side effects were far less severe than those typically seen with the standard vein-based treatment. No patient experienced the life-threatening systemic infections or severe bone marrow suppression that often accompany the heavy chemotherapy required for intravenous therapy. While one patient did experience temporary confusion and sleepiness, a known side effect of immune activation in the brain, it resolved quickly with standard medical care. The study suggests that by keeping the treatment localized to the central nervous system, the immune system can fight the cancer effectively without triggering a dangerous storm of inflammation throughout the rest of the body.

To understand exactly what was happening inside the patients, the researchers analyzed samples of the cerebrospinal fluid and blood using advanced genetic sequencing. They discovered that the treatment triggered a dynamic reshaping of the immune environment within the brain. Before the treatment, the fluid was dominated by cancer cells with very few immune defenders. After the infusion, the engineered T-cells multiplied rapidly within the fluid, directly attacking the tumor. The researchers also observed a fascinating shift in the behavior of neutrophils, a type of white blood cell that acts as a first responder to infection. They found that these cells changed their identity as the disease progressed. Initially, they appeared in a state associated with moving toward the site of trouble. As the treatment worked and the cancer receded, these cells transformed into a different state focused on inflammation and cleaning up the battlefield. However, if the cancer returned, the cells shifted again into a state associated with aging and a less effective immune response. This detailed map of how immune cells change over time provides a new window into how the body fights cancer in the brain and why some treatments succeed while others fail.

The study also highlighted a practical advantage for patients who are too weak to tolerate the standard preparation. Because the treatment was delivered directly into the fluid, it did not require the aggressive chemotherapy that wipes out the body's existing immune cells. This makes the therapy a viable option for older patients or those with poor bone marrow function who would otherwise be excluded from receiving CAR-T therapy. The researchers noted that the engineered cells expanded well within the cerebrospinal fluid, reaching high levels that correlated with the disappearance of the cancer. While the cells were less detectable in the blood, this was actually a good sign, indicating that the treatment was staying where it was needed rather than circulating uselessly through the rest of the body. The median survival time for patients receiving this direct treatment was longer than that of similar patients treated with the standard intravenous method, suggesting that this approach could offer a meaningful extension of life for those with this difficult form of cancer.

Despite these promising findings, the researchers are careful to note the limitations of their work. The study involved a small number of patients from a single center, which means the results need to be confirmed in larger groups before this method can be considered a standard treatment. The follow-up period was also relatively short, so the long-term durability of the remissions remains to be seen. Additionally, the study did not fully solve the problem of how long the engineered cells can survive in the cerebrospinal fluid, as they tend to disappear faster there than in the blood. The team suggests that future strategies might involve giving repeated doses or combining this local approach with other treatments to keep the cancer in check for years. Nevertheless, this work demonstrates that delivering powerful immune therapies directly to the site of the disease is a safe and feasible strategy that avoids many of the toxic side effects of current methods. It offers a new path forward for patients who have run out of options, turning a difficult barrier into a direct route for healing.